EndoPredict Publications
2019
Dec 2019
Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EPclin) use (UCBG 2-14).
Penault-Llorca F, Kwiatkowski F, Arnaud A, Levy C, Leheurteur M, Uwer L, Derbel O, Le Rol A, Jacquin JP, Jouannaud C, Quenel-Tueux N, Girre V, Foa C, Guardiola E, Lortholary A, Catala S, Guiu S, Valent A, Boinon D, Lemonnier J, Delaloge S.
Breast. 2020; 49:132-40. [In Progress]
https://www.sciencedirect.com/journal/the-breast/vol/49/suppl/C
Aug 2019
Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay.
Soliman H, Flake II DD, Magliocco A, Robson M, Schwartzberg L, Sharma P, Brown K, Wehnelt S, Kronenwett R, Gutin A, Lancaster J, Cuzick J, Gradishar W.
JCO Precis Oncol 2019 [Epub ahead of print]
https://ascopubs.org/doi/10.1200/PO.18.00361
May 2019
Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.
Filipits M, Dubsky P, Rudas M, Greil R, Balic M, Bago-Horvath Z, Singer C, Hlauschek D, Brown K, Bernhisel R, Kronenwett R, Lancaster J, Fitzal F, Gnant M.
Clin Cancer Res. 2019;25:3865-72.
https://www.ncbi.nlm.nih.gov/pubmed/?term=Prediction+of+Distant+Recurrence+using+EndoPredict+among+Women+with+ER%2B%2C+HER2-+Node-+Positive+and+Node-Negative+Breast+Cancer+Treated+with+Endocrine+Therapy+Only.
Apr 2019
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
Sestak I, Martin M, Dubsky P, Kronenwett R, Rojo F, Cuzick J, Filipits M, Ruiz A, Gradishar W, Soliman H, Schwartzberg L, Buus R, Hlauschek D, Rodriguez A, Gnant M.
Breast Cancer Res Treat. 2019; 176:377-86.
https://www.ncbi.nlm.nih.gov/pubmed/31041683
2018
Dec 2018
EndoPredict prognostic signature in pN1mi, estrogen receptor-positive breast cancer: analysis of the French national registry for molecular signatures.
Lacroix-Triki M, Arnould L, MacGrogan G, Penault-Llorca F, Haudebourg J, Tas P, Garnier A, Vincent-Salomon A, Miquel C, Lehmann-Che J, Callens C, Quillien V, Cayre A, Lamy PJ, Rouleau E, de Cremoux P.
Poster: SABCS 2018; P4-08-23.
https://cancerres.aacrjournals.org/content/79/4_Supplement/P4-08-23
Dec 2018
Change in therapeutic management after EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients.
Villarreal-Garza C, Deneken-Hernandez Z, Maffuz-Aziz A, Lopez-Martinez EA, Muñoz-Lozano JF, Barragan-Carrillo R, Peña-Curiel O, Moreno-Jaime B, Ramos-Elias P, Diaz H, Bautista-Piña V, Garcia-Garcia M, Mesa-Chavez F.
Poster: SABCS 2018; P2-08-54.
https://cancerres.aacrjournals.org/content/79/4_Supplement/P2-08-54
Dec 2018
RESCUE: REACHING FOR EVIDENCE-BASED CHEMOTHERAPY USE IN ENDOCRINE SENSITIVE BREAST CANCER, A prospective health care study on risk assessment by the clinicomolecular test EndoPredict® and long-term patient outcome in early luminal breast cancer.
Ettl J, Blohmer J-U, Denkert C, Keller M, Klein E, Kronenwett R, Neuser P, Paepke S, Schade-Brittinger C, Schnuppe K, Untch M, Wittenberg M, Kiechle M.
Poster: SABCS 2018; OT1-12-03.
https://cancerres.aacrjournals.org/content/79/4_Supplement/OT1-12-03
Jul 2018
Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinicomolecular predictor.
Loibl S, Weber K, Huober J, Krappmann K, Marmé F, Schem C, Engels K, Pfitzner BM, Kümmel S, Furlanetto J, Hartmann A, Darb-Esfahani S, Müller V, Staebler A, von Minckwitz G, Kronenwett R, Denkert C.
Clin Cancer Res. 2018;24:3358-65.
https://www.ncbi.nlm.nih.gov/pubmed/?term=Risk+assessment+after+neoadjuvant+chemotherapy+in+luminal+breast+cancer+using+a+clinicomolecular+predictor.
Jun 2018
In silico evaluation of the 12-gene molecular score (EndoPredict) and the recurrence score (Oncotype DX) as predictors of response to neoadjuvant chemotherapy in estrogen receptor positive, HER2 negative breast cancer.
Soliman H, Robson M, Wagner S, Flake II DD, Schwartzberg L, Sharma P, Magliocco A, Kronenwett R, Lancaster J, Lanchbury JS, Gutin A, Gradishar W.
Abstract: J Clin Oncol 36, 2018 (suppl; abstr 539).
https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.539
Jun 2018
Predicting expected absolute chemotherapy treatment benefit in women with early-stage breast cancer using a 12-gene expression assay.
Gradishar W, Robson M, Flake II DD, Schwartzberg L, Sharma P, Soliman H, Magliocco A, Brown K, Wehnelt S, Gutin A, Kronenwett R, Lancaster J.
Abstract: J Clin Oncol 36, 2018 (suppl; abstr 525).
https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.525
May 2018
First French pilot quality assessment of the EndoPredict test for early luminal breast carcinoma.
Lehmann-Che J, Miquel C, Wong J, Callens C, Rouleau E, Quillien V, Lozano N, Cayre A, Lacroix L, Bieche I, Bertheau P, Teixeira L, Llorca FP, Lamy PJ, DE Cremoux P; GFCO GROUP.
Anticancer Res. 2018;38:2909-14.
https://www.ncbi.nlm.nih.gov/pubmed/?term=First+French+pilot+quality+assessment+of+the+EndoPredict+test+for+early+luminal+breast+carcinoma.
Apr 2018
Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial.
Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, Ferree S, Sgroi D, Schnabel C, Baehner FL, Mallon E, Dowsett M.
JAMA Oncol. 2018;4:545-53.
https://www.ncbi.nlm.nih.gov/pubmed/?term=Comparison+of+the+performance+of+6+prognostic+signatures+for+estrogen+receptor-positive+breast+cancer%3A+a+secondary+analysis+of+a+randomized+clinical+trial.
2017
Sep 2017
Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer.
Peláez-García A, Yébenes L, Berjón A, Angulo A, Zamora P, Sánchez-Méndez JI, Espinosa E, Redondo A, Heredia-Soto V, Mendiola M, Feliú J, Hardisson D.
PLoS One. 2017;12:e0183452.
https://www.ncbi.nlm.nih.gov/pubmed/?term=Comparison+of+risk+classification+between+EndoPredict+and+MammaPrint+in+ER-positive%2FHER2-negative+primary+invasive+breast+cancer.
